Tibsovo
NICE Recommends Servier's Tibsovo With Chemo for Newly Diagnosed IDH1-Mutant AML
The institute estimated that around 130 AML patients with IDH1-mutated disease will be eligible for this treatment in England.
Servier Nabs Tibsovo FDA Approval in IDH1-Mutated Myelodysplastic Syndromes
The FDA simultaneously approved Abbott Diagnostics' IDH1 test as a companion diagnostic to select IHD1-mutated relapsed or refractory MDS patients for Tibsovo.
Servier Garners FDA Priority Review for Tibsovo Regulatory Filing in IDH1-Mutant MDS
The agency will review data Servier has submitted from a Phase I trial showing an 83.3 percent objective response rate and issue a decision by February 2024.